Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dendritic cell loaded livin peptide
- Development stage
- Unknown
- Lead developer
- Third Military Medical University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, Peptides
- Administration
- Intravenous
01
Overview
Dendritic cell loaded livin peptide is an autologous dendritic cell (DC) vaccine designed to treat non-small cell lung cancer (NSCLC). The therapy involves harvesting a patient's own dendritic cells and pulsing them with peptides derived from Livin (also known as BIRC7), a member of the Inhibitor of Apoptosis Protein (IAP) family that is frequently overexpressed in various malignancies and associated with resistance to therapy. These antigen-loaded DCs are then re-administered to the patient to prime and activate a specific cytotoxic T lymphocyte (CTL) response against tumor cells expressing the Livin protein. In clinical studies, this cell therapy has been investigated as a sensitization agent to enhance the efficacy of radiotherapy in patients with middle or terminal stage NSCLC, often in conjunction with cytokine-induced killer (CIK) cell therapy.
- Other names
- DC loaded Livin peptideLivin-peptide-pulsed dendritic cellsdendritic cells load the livin peptide
02
Targets
BIRC7 (Baculoviral IAP repeat-containing protein 7 (Livin))MHC I (MHC class I})TCR (T-cell receptor recognizing livin-derived peptide–MHC class I complex)
Beyond the preview
Go deeper on dendritic cell loaded livin peptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dendritic cell loaded livin peptide.